1
|
Proudman W, Kleinig O, Lam L, Collins L, Bagster M, Gupta A, Kovoor J, Bacchi S, Slee M, Chan W. The Icepack Test in the Diagnosis of Myasthenia Gravis with Ocular Features: A Systematic Review of Diagnostic Accuracy, Technique, and Economic Utility. Semin Ophthalmol 2023; 38:679-685. [PMID: 36967601 DOI: 10.1080/08820538.2023.2194984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 03/14/2023] [Accepted: 03/16/2023] [Indexed: 03/29/2023]
Abstract
BACKGROUND The diagnosis of myasthenia gravis (MG) may be challenging and require multiple specialised testing modalities. Accessing these investigations can involve significant waiting time and costs. The bedside icepack test (IPT) has been proposed to assist with the diagnosis of MG with ocular features, and may prove an economically viable; however, there have been there is heterogeneity in the literature evaluating the IPT. OBJECTIVES A systematic review was performed examining the accuracy, described techniques, and economic implications of the IPT for the diagnosis of MG with ocular features. METHOD The databases EMBASE, PubMed, and the Cochrane Library were searched from inception to July 2022. The systematic review adhered to PRISMA guidelines. Eligibility determination was undertaken with a standardised form using appropriate inclusion criteria. The Cochrane risk of bias assessment tool for diagnostic test accuracy was employed to evaluate studies that presented the diagnostic performance of the IPT. The Johanna Briggs Institute Critical Appraisal Checklist for Economic Evaluations was used for the assessment of studies presenting economic evaluations of the IPT. RESULTS 20 articles met the specified criteria and included a total of 1264 participants. The IPT had a sensitivity ranging from 38.5% to 100%. Specificity was found to be > 95% in six studies. Excluding two outlier results of 25% and 31.3%, the lowest specificity recorded was 62.5%. The most commonly described method of evaluating the IPT involved applying ice to both eyelids and using a >2 mm change as a threshold for a positive test (evaluated with a ruler). There were no adverse effects described with the IPT. There were no studies that formally examined the economic implications of the IPT. CONCLUSIONS The IPT is a well-tolerated and readily available diagnostic tool that has an important role in the evaluation of possible MG with ocular features in specific contexts. Despite limited economic evaluation of this test, it is likely the use of the IPT may result in significant financial and time savings.
Collapse
Affiliation(s)
| | | | - Lydia Lam
- University of Adelaide, Adelaide, SA, Australia
| | - Luke Collins
- Flinders Medical Centre, Bedford Park, SA, Australia
| | | | - Aashray Gupta
- Gold Coast University Hospital, Southport, Australia
| | - Joshua Kovoor
- University of Adelaide, Adelaide, SA, Australia
- Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Stephen Bacchi
- University of Adelaide, Adelaide, SA, Australia
- Flinders Medical Centre, Bedford Park, SA, Australia
- Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Mark Slee
- Flinders Medical Centre, Bedford Park, SA, Australia
| | - WengOnn Chan
- University of Adelaide, Adelaide, SA, Australia
- Royal Adelaide Hospital, Adelaide, SA, Australia
| |
Collapse
|
2
|
Behbehani R. Ocular Myasthenia Gravis: A Current Overview. Eye Brain 2023; 15:1-13. [PMID: 36778719 PMCID: PMC9911903 DOI: 10.2147/eb.s389629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 01/24/2023] [Indexed: 02/05/2023] Open
Abstract
Ocular myasthenia gravis (OMG) is a neuromuscular disease characterized by autoantibody production against post-synaptic proteins in the neuromuscular junction. The pathophysiological auto-immune mechanisms of myasthenia are diverse, and this is governed primarily by the type of autoantibody production. The diagnosis of OMG relies mainly on clinical assessment, the use of serological antibody assays for acetylcholine receptors (AchR), muscle-specific tyrosine kinase (MusK), and low-density lipoprotein 4 (LPR4). Other autoantibodies against post-synaptic proteins, such as cortactin and agrin, have been detected; however, their diagnostic value and pathogenic effect are not yet clearly defined. Clinical tests such as the ice test and electrophysiologic tests, particularly single-fiber electromyography, have a valuable role in diagnosis. The treatment of OMG is primarily through cholinesterase inhibitors (pyridostigmine), and steroids are frequently required in cases of ophthalmoplegia. Other immunosuppressive therapies include antimetabolites (azathioprine, mycophenolate mofetil, methotrexate) and biological agents such as B-cell depleting agents (Rituximab) and complement inhibitors (eculizumab). Evidence is scarce on the effect of immunosuppressive therapy on altering the natural course of OMG. Clinicians must be vigilant of a myasthenic syndrome in patients using immune-check inhibitors. Reliable and consistent biomarkers are required to assess disease severity and response to therapy to optimize the management of OMG. The purpose of this review is to summarize the current trends and the latest developments in diagnosing and treating OMG.
Collapse
Affiliation(s)
- Raed Behbehani
- Neuroophthalmology Unit, Ibn Sina Hospital, Kuwait City, Kuwait,Correspondence: Raed Behbehani, Ibn Sina Hospital, P.O Box 1180, Tel +965 2224 2999, Fax +965 2249 2406, Email
| |
Collapse
|
3
|
Kim DH, Roh HC, Oh SY. Ophthalmologic clinical features of ocular myasthenia gravis. Medicine (Baltimore) 2023; 102:e31972. [PMID: 36637960 PMCID: PMC9839294 DOI: 10.1097/md.0000000000031972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
To investigate the clinical features of ocular myasthenia gravis (OMG) in ophthalmology. A total of 28 patients with ptosis or diplopia who were followed for at least 6 months between March 2016 and February 2022 were included in this study. The clinical symptoms of the patients and test results were analyzed. According to the positivity of serologic or electrophysiologic test, these patients were divided into 2 groups (positive and negative OMG results) and according to the clinical symptoms of diplopia or ptosis for comparison. Ptosis, diplopia, and both ptosis and diplopia were present in 6 (21.43%), 14 (50.0%), and 8 (28.57%) patients, respectively. Acetylcholine receptor auto-antibody (AchR Ab) was positive in 16 (57.14%) of 28 patients and the ice test was positive in 13 (92.86%) of 14 patients with ptosis. Abnormal thymic lesions were presented in 7 (25.0%) patients, and a definite improvement in response to pyridostigmine was observed in 27 (100.0%) patients. Both ptosis and diplopia were significantly higher in the group with positive results than that in the negative results group (P = .025). In addition, both horizontal and vertical diplopia was significantly higher in the group with AchR Ab titer > 5.0 than that in the group with AchR Ab titer < 5.0 (P = .041). After excluding cranial nerve palsy, if there is ptosis and diplopia, especially vertical diplopia, the possibility of OMG should be considered.
Collapse
Affiliation(s)
- Do-Hyung Kim
- Department of Neurology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - Hyeon Cheol Roh
- Department of Ophthalmology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - Shin Yeop Oh
- Department of Ophthalmology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
- * Correspondence: Shin Yeop Oh, Department of Ophthalmology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon 51353, Republic of Korea (e-mail: )
| |
Collapse
|
4
|
Abstract
BACKGROUND Around 60%--75% of myasthenia gravis (MG) patients initially present with nonspecific ocular symptoms. Failed recognition of these symptoms may delay the diagnosis of MG up to 5 years or more, leading to a reduced likelihood of remission and increased morbidity. Current diagnostic tests are either poorly sensitive for patients presenting with ocular symptoms alone or are time consuming, invasive, require a high level of technical expertise, and generally are universally difficult to obtain. This review will explore quantitative eye and pupil tracking as a potential noninvasive, time-effective, and less technically demanding alternative to current diagnostic tests of MG. EVIDENCE ACQUISITION Comprehensive literature review. RESULTS Thirty-two publications using oculography for the diagnosis of MG and 6 studies using pupillometry were evaluated. In MG patients, extra ocular muscle fatigue was evident in reports of intersaccadic, intrasaccadic and postsaccadic abnormalities, changes in optokinetic nystagmus, slow eye movements, disconjugate saccades, and pupillary constrictor muscle weakness. CONCLUSIONS Our review identified several potentially useful variables that derive from oculography and pupillometry studies that could assist with a timely diagnosis of MG. Limitations of this review include heterogeneity in design, sample size, and quality of the studies evaluated. There is a need for larger, well-designed studies evaluating eye-tracking measures in the diagnosis of MG, especially for patients presenting with purely ocular symptoms.
Collapse
|
5
|
Wong SH. Clinical Signs in Neuro-Ophthalmology: Eye Signs in Myasthenia Gravis. Ann Indian Acad Neurol 2022; 25:S91-S93. [PMID: 36589038 PMCID: PMC9795714 DOI: 10.4103/aian.aian_163_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 03/06/2022] [Accepted: 03/10/2022] [Indexed: 01/04/2023] Open
Abstract
A hallmark of myasthenia gravis (MG) is the variability and fatigability of striated muscles. The majority of people with MG have eye symptoms of ptosis and diplopia. This paper outlines the eye signs in MG, including practical tips on the examination technique relevant to MG, and pitfalls to avoid.
Collapse
Affiliation(s)
- Sui Hsien Wong
- Moorfields Eye Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, King's College London, University College London, London, United Kingdom,Address for correspondence: Dr. Sui Hsien Wong, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, United Kingdom. E-mail:
| |
Collapse
|
6
|
Oh JK, Shinder R, Hodgson NM. Ptosis With Fluctuating Diplopia. JAMA Ophthalmol 2022; 140:538-539. [PMID: 35266992 DOI: 10.1001/jamaophthalmol.2021.5629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Jin Kyun Oh
- Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York.,Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York
| | - Roman Shinder
- Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York.,Department of Otolaryngology, SUNY Downstate Medical Center, Brooklyn, New York
| | - Nickisa M Hodgson
- Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York
| |
Collapse
|
7
|
Bedside and laboratory diagnostic testing in myasthenia. J Neurol 2022; 269:3372-3384. [PMID: 35142871 PMCID: PMC9119875 DOI: 10.1007/s00415-022-10986-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 01/18/2022] [Accepted: 01/19/2022] [Indexed: 11/02/2022]
Abstract
Myasthenia gravis (MG) and congenital myasthenic syndromes (CMS) are a group of disorders with a well characterised autoimmune or genetic and neurophysiological basis. We reviewed the literature from the last 20 years assessing the utility of various neurophysiological, immunological, provocative and genetic tests in MG and CMS. Diagnostic sensitivity of repetitive nerve stimulation test ranges between 14 and 94% and specificity between 73 and 100%; sensitivity of single-fibre EMG (SFEMG) test ranges between 64 and 100% and specificity between 22 and 100%; anti-acetylcholine receptor (AChR) antibody sensitivity ranges from 13 to 97% and specificity ranges from 95 to 100%. Overall, SFEMG has the highest sensitivity while positive anti-AChR antibodies have the highest specificity. Newer testing strategies that have been investigated over the last couple of decades include ocular vestibular-evoked myogenic potentials, otoacoustic emissions and disease-specific circulating miRNAs in serum for autoimmune myasthenia, as well as next-generation sequencing for genetic testing of CMS. While there has been significant progress in developing newer testing strategies for diagnosing MG and CMS over the last couple of decades, more research is needed to assess the utility of these newer tools regarding their sensitivity and specificity.
Collapse
|
8
|
Behbehani R, Ali A, Al-Moosa A. Ocular Myasthenia: Clinical Course and the Diagnostic Utility of Assaying Acetylcholine Receptor Antibodies. Neuroophthalmology 2022; 46:220-226. [PMID: 35859633 PMCID: PMC9291698 DOI: 10.1080/01658107.2022.2037662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
Myasthenia gravis (MG) is an autoimmune disease that causes neuromuscular junction transmission defect and has a predilection for the with neuromuscular junction transmission defect and predilection for extra-ocular and eyelid muscles. Most cases of ocular MG (OMG) convert later to generalised MG (GMG). Assaying acetylcholine receptor antibodies (AchRA) has been used to diagnose MG, but the reported sensitivity in OMG is lower (50%) than in GMG. We report the clinical course and the diagnostic yield of assaying AchRA in a Kuwaiti cohort of patients with OMG. We carried out a retrospective review of 47 patients diagnosed with OMG who were tested for AchRA. Ancillary tests included the ice test, single-fibre electromyography (SFMEG), and repetitive nerve stimulation electromyography (RNS). Progression to GMG occurred in 51% of OMG patients with a mean time to progression of 12.1 months (range 4 to 20 months). AchRAs were positive in 46 of 47 cases (98%), while SFEMG was positive in 31 of 34 cases (91.1%). Older age (44.25 years versus 38 years, p < .05) and higher AchRA titre (2.0 nmol/L versus 1.27 nmol/L, p < .05) were significantly associated with conversion to GMG. We have found a high rate of AchRA seropositivity in relatively younger subjects of OMG. Higher AchRA titres and older age were associated with conversion to GMG, usually within the first 2 years.
Collapse
Affiliation(s)
- Raed Behbehani
- Al-Bahar Ophthalmology Center, IBN SINA Hospital, Kuwait
| | - Abdullah Ali
- Al-Bahar Ophthalmology Center, IBN SINA Hospital, Kuwait
| | | |
Collapse
|
9
|
Kim H, Oh SY. Diagnostic yields and clinical features of ocular myasthenia gravis. Medicine (Baltimore) 2021; 100:e26457. [PMID: 34160444 PMCID: PMC8238339 DOI: 10.1097/md.0000000000026457] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 06/05/2021] [Indexed: 01/04/2023] Open
Abstract
To investigate clinical features and diagnosis process of ocular myasthenia gravis (OMG) in ophthalmology department.A total of 36 patients with ptosis or diplopia who had follow-up for at least 3 months between March 2016 and December 2019 were included in this study. Clinical symptoms of patients and the test results were analyzed. According to the positivity of serologic test, these patients were divided into 2 groups (confirmed OMG and possible OMG with relief of symptoms after antimyasthenic treatment) for comparison.Ptosis was present in 12 (33.33%) patients, diplopia was present in 14 (38.89%) patients, and both ptosis and diplopia were present in 10 (27.78%) patients. Acetylcholine receptor auto-antibody (AchR Ab) was positive in 14 (38.89%) of 36 patients and ice test was positive in 15 (71.43%) of 21 patients with ptosis. Unequivocal response to pyridostigmine was observed in 31 (86.11%) patients. For seropositive cases, AchR Ab titer was significantly higher in the group with 2 clinical symptoms than that in the 1 clinical symptom (P = .011).This study presents the usefulness and diagnostic validity of antimyasthenic treatment for OMG, especially seronegative OMG, with detailed symptom analysis.
Collapse
Affiliation(s)
- Hyuna Kim
- Department of Ophthalmology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul
| | - Shin Yeop Oh
- Department of Ophthalmology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
| |
Collapse
|
10
|
Saint-Gerons M, Rubio MA, Martinez A, Matheu A. Quantification of Cover Test Prior and Post Pyridostigmine in Diagnosis of Myasthenia Gravis. J Binocul Vis Ocul Motil 2021; 71:71-76. [PMID: 33877951 DOI: 10.1080/2576117x.2021.1904097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 03/04/2021] [Accepted: 03/12/2021] [Indexed: 06/12/2023]
Abstract
Objective: To assess the value of measuring diplopia before and after pyridostigmine intake to differentiate myasthenia gravis from sagging eye syndrome.To establish a threshold for a positive response to pyridostigmine in the diagnosis of myasthenia gravis.Methods: 15 patients with myasthenia gravis and 15 with sagging eye syndrome diplopia were evaluated. Diplopia was measured in five positions (upgaze, downgaze, right gaze, left gaze, and primary position). After baseline measurements, the patient received a single dose (60 mg) of pyridostigmine. After 60 minutes the prism measure was performed again in five positions. Horizontal deviation, vertical deviation at distance was compared before and after a single dose of pyridostigmine in each gaze. Ocular deviations were compared between the two groups to identify the threshold with the highest sensitivity and specificity.Results: Differences between pretest deviations and posttest deviations in any gaze were found to be statistically significant only in the MG group. The optimum threshold for a positive response to pyridostigmine was a reduction of 2 prism diopters in any component in any gaze. Sensitivity for the detection of myasthenia diplopia was 80.00% and specificity was 86.67%.Conclusions: Our results suggest that measuring diplopia with prisms before and after pyridostigmine administration can help to detect patients with suspected myasthenia.
Collapse
Affiliation(s)
- Marta Saint-Gerons
- Unit of Neurophthalmology, Consorci Parc de Salut MAR de Barcelona, Barcelona, Spain
- Department of Ophthalmology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Miguel Angel Rubio
- Unit of Neurophthalmology, Consorci Parc de Salut MAR de Barcelona, Barcelona, Spain
- Unit of Neuromuscular Diseases, Consorci Parc de Salut MAR de Barcelona, Barcelona, Spain
| | - Ana Martinez
- Department of Ophthalmology, Universitat Autònoma de Barcelona, Barcelona, Spain
- Ophthalmology, Consorci Parc de Salut MAR de Barcelona, Barcelona, Spain
| | - Ana Matheu
- Unit of Neurophthalmology, Consorci Parc de Salut MAR de Barcelona, Barcelona, Spain
| |
Collapse
|
11
|
Evoli A, Iorio R. Controversies in Ocular Myasthenia Gravis. Front Neurol 2020; 11:605902. [PMID: 33329368 PMCID: PMC7734350 DOI: 10.3389/fneur.2020.605902] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2020] [Accepted: 10/26/2020] [Indexed: 12/12/2022] Open
Abstract
Myasthenia gravis (MG) with symptoms limited to eye muscles [ocular MG (OMG)] is a rare disease. OMG incidence varies according to ethnicity and age of onset. In recent years, both an increase in incidence rate, particularly in the elderly, and a lower risk for secondary generalization may have contributed to the growing disease prevalence in Western countries. OMG should be considered in patients with painless ptosis and extrinsic ophthalmoparesis. Though asymmetric muscle involvement and symptom fluctuations are typical, in some cases, OMG can mimic isolated cranial nerve paresis, internuclear ophthalmoplegia, and conjugate gaze palsy. Diagnostic confirmation can be challenging in patients negative for anti-acetylcholine receptor and anti-muscle-specific tyrosine kinase antibodies on standard radioimmunoassay. Early treatment is aimed at relieving symptoms and at preventing disease progression to generalized MG. Despite the absence of high-level evidence, there is general agreement on the efficacy of steroids at low to moderate dosage; immunosuppressants are considered when steroid high maintenance doses are required. The role of thymectomy in non-thymoma patients is controversial. Prolonged exposure to immunosuppressive therapy has a negative impact on the health-related quality of life in a proportion of these patients. OMG is currently excluded from most of the treatments recently developed in generalized MG.
Collapse
Affiliation(s)
- Amelia Evoli
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.,Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Raffaele Iorio
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.,Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
12
|
Giannoccaro MP, Paolucci M, Zenesini C, Di Stasi V, Donadio V, Avoni P, Liguori R. Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis. Neurology 2020; 95:e1800-e1806. [PMID: 32788239 DOI: 10.1212/wnl.0000000000010619] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 04/14/2020] [Indexed: 01/30/2023] Open
Abstract
OBJECTIVE To compare the diagnostic accuracy of ice pack test (IPT) and single-fiber EMG (SF-EMG) in patients with suspected ocular myasthenia (OM) presenting with ptosis. METHODS We studied consecutive patients referred for the clinical suspicion of OM. Patients underwent IPT and stimulated SF-EMG on the orbicularis oculi muscle. Receiver operating characteristic curve analysis was performed to determine the accuracy of IPT, SF-EMG, and their combination. RESULTS We included 155 patients, 102 with OM and 53 with other diagnosis (OD). The IPT had a sensitivity of 86% (95% confidence interval [CI] 79-93) and a specificity of 79% (95% CI 68-90). SF-EMG showed a sensitivity of 94% (95% CI 89-98) and a specificity of 79% (95% CI 68-90). Overall, IPT and SF-EMG showed discordant results in 30 cases, 16 OM and 14 OD. The combination of IPT and SF-EMG, using the positivity of at least one test for OM diagnosis, increased the sensitivity to 98% (95% CI 95-100), reducing the specificity to 66% (95% CI 53-78), whereas using the positivity of both tests, we obtained a sensitivity of 82% (95% CI 75-90) and a specificity of 92% (95% CI 85-99). The negativity of both tests had a 94% (95% CI 87-100) negative predictive value. Comparison of the areas under the curve showed no differences in the diagnostic accuracy of IPT, SF-EMG, and their combinations. CONCLUSIONS IPT and SF-EMG have similar diagnostic accuracy in patients with OM presenting with ptosis. The negativity of both tests strongly suggests another diagnosis. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that both the IPT and SF-EMG accurately identify patients with OM.
Collapse
Affiliation(s)
- Maria Pia Giannoccaro
- From the Dipartimento di Scienze Biomediche e Neuromotorie (M.P.G., P.A., R.L.), Università di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (M.P.G., C.Z., V.D.S., V.D., P.A., R.L.); UO Neurosonologia e Cefalee (M.P.), Università Campus Bio-Medico, Rome; and UO Neurologia (M.P.), Ospedale M. Bufalini, Cesena, AUSL Romagna, Italy.
| | - Matteo Paolucci
- From the Dipartimento di Scienze Biomediche e Neuromotorie (M.P.G., P.A., R.L.), Università di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (M.P.G., C.Z., V.D.S., V.D., P.A., R.L.); UO Neurosonologia e Cefalee (M.P.), Università Campus Bio-Medico, Rome; and UO Neurologia (M.P.), Ospedale M. Bufalini, Cesena, AUSL Romagna, Italy
| | - Corrado Zenesini
- From the Dipartimento di Scienze Biomediche e Neuromotorie (M.P.G., P.A., R.L.), Università di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (M.P.G., C.Z., V.D.S., V.D., P.A., R.L.); UO Neurosonologia e Cefalee (M.P.), Università Campus Bio-Medico, Rome; and UO Neurologia (M.P.), Ospedale M. Bufalini, Cesena, AUSL Romagna, Italy
| | - Vitantonio Di Stasi
- From the Dipartimento di Scienze Biomediche e Neuromotorie (M.P.G., P.A., R.L.), Università di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (M.P.G., C.Z., V.D.S., V.D., P.A., R.L.); UO Neurosonologia e Cefalee (M.P.), Università Campus Bio-Medico, Rome; and UO Neurologia (M.P.), Ospedale M. Bufalini, Cesena, AUSL Romagna, Italy
| | - Vincenzo Donadio
- From the Dipartimento di Scienze Biomediche e Neuromotorie (M.P.G., P.A., R.L.), Università di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (M.P.G., C.Z., V.D.S., V.D., P.A., R.L.); UO Neurosonologia e Cefalee (M.P.), Università Campus Bio-Medico, Rome; and UO Neurologia (M.P.), Ospedale M. Bufalini, Cesena, AUSL Romagna, Italy
| | - Patrizia Avoni
- From the Dipartimento di Scienze Biomediche e Neuromotorie (M.P.G., P.A., R.L.), Università di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (M.P.G., C.Z., V.D.S., V.D., P.A., R.L.); UO Neurosonologia e Cefalee (M.P.), Università Campus Bio-Medico, Rome; and UO Neurologia (M.P.), Ospedale M. Bufalini, Cesena, AUSL Romagna, Italy
| | - Rocco Liguori
- From the Dipartimento di Scienze Biomediche e Neuromotorie (M.P.G., P.A., R.L.), Università di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (M.P.G., C.Z., V.D.S., V.D., P.A., R.L.); UO Neurosonologia e Cefalee (M.P.), Università Campus Bio-Medico, Rome; and UO Neurologia (M.P.), Ospedale M. Bufalini, Cesena, AUSL Romagna, Italy
| |
Collapse
|
13
|
Dagi LR, Velez FG, Archer SM, Atalay HT, Campolattaro BN, Holmes JM, Kerr NC, Kushner BJ, Mackinnon SE, Paysse EA, Pihlblad MS, Pineles SL, Strominger MB, Stager DR, Stager D, Capo H. Adult Strabismus Preferred Practice Pattern®. Ophthalmology 2020; 127:P182-P298. [DOI: 10.1016/j.ophtha.2019.09.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Accepted: 09/20/2019] [Indexed: 11/25/2022] Open
|
14
|
Kee HJ, Yang HK, Hwang JM, Park KS. Evaluation and validation of sustained upgaze combined with the ice-pack test for ocular myasthenia gravis in Asians. Neuromuscul Disord 2019; 29:296-301. [DOI: 10.1016/j.nmd.2018.12.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Revised: 09/28/2018] [Accepted: 12/18/2018] [Indexed: 11/29/2022]
|
15
|
Abstract
PURPOSE OF REVIEW Myasthenia gravis is an autoimmune disease that commonly affects the palpebral and extraocular muscles. Ocular myasthenia gravis (OMG) is a variant of the disease that is confined to the ocular muscles but frequently becomes generalized over time. The diagnosis of OMG is often challenging but both clinical and laboratory findings are helpful in confirming the clinical suspicion. This review provides an update on the diagnostic approach and therapeutic options for OMG. RECENT FINDINGS Antimuscle-specific tyrosine kinase and LDL-related receptor-related protein 4 are newly available serologic testing for myasthenia gravis that can help in increasing the diagnostic sensitivity of OMG. They should be included to the diagnostic algorithm of OMG in appropriate clinical situations. SUMMARY OMG remains a primarily clinical diagnosis, but recent advances in laboratory testing can improve the diagnostic accuracy and should be used in appropriate clinical settings. The mainstay of treatment for OMG has not significantly changed over the past years, but the increasing availability of steroid-sparing agents improved the disease control while minimizing steroid-induced complications.
Collapse
|
16
|
What is in the Neuromuscular Junction Literature? J Clin Neuromuscul Dis 2018; 20:76-84. [PMID: 30439753 DOI: 10.1097/cnd.0000000000000218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This update begins with myasthenia gravis and the roles of anti-agrin and cortactin antibodies. Regarding diagnosis, a report on repeated ice pack testing is highlighted as are several reports on the close correlation of electrodiagnostic testing with clinical features and the response to treatment. The incidence of head drop and associated clinical and ventilatory features are gleaned from a retrospective study. We also discuss a study that assessed the predominantly symmetric and conjugate ocular findings in MuSK-myasthenia gravis. Other topics that are covered include quality of life and preoperative risk. We then summarize the positive treatment trials of subcutaneous immunoglobulin and eculizumab. Turning to Lambert-Eaton Myasthenic Syndrome, we report on an epidemiologic study performed on the veteran affairs population, the results of the DAPPER study of 3, 4 diaminopyridine, and look to the future for other treatment options involving calcium gating modifiers.
Collapse
|
17
|
Marinos E, Buzzard K, Fraser CL, Reddel S. Evaluating the temperature effects of ice and heat tests on ptosis due to Myasthenia Gravis. Eye (Lond) 2018; 32:1387-1391. [PMID: 29743585 PMCID: PMC6085283 DOI: 10.1038/s41433-018-0101-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 04/05/2018] [Accepted: 04/11/2018] [Indexed: 11/08/2022] Open
Abstract
AIMS The aims of this study are as follows: (1) to describe a standardised methodology for the ice test, and where necessary a heat test; (2) to determine the effects of local cooling vs. heating on ptosis in myasthenia gravis (MG) patients. METHODS Twenty-three MG patients with ptosis were identified from a tertiary referral neuroimmunology clinic, seventeen with significant ptosis ≥2 mm. Latex party balloons were filled with ice and cold tap water for the ice test, or with water heated to 45 °C for the heat test. Each test was performed for 2 min, with ruler measurement and photographs taken of the palpebral aperture before and immediately after each test. RESULTS This standardised method was efficient in a clinical setting while maintaining efficacy. In all 23 patients, the mean improvements in ptosis with the ice, rest, and heat tests were 2.3 (±1.5) mm, 1.3 (±1.1) mm, and 0.33 (±1.4) mm respectively. In the 17 patients with significant ptosis, the mean improvements in ptosis with the ice, rest, and heat tests were 2.9 (±1.2) mm, 1.8 (±0.92) mm, and 0.83 (±1.4) mm, respectively. In these 17 patients, the ice test improved ptosis by 1.3 mm more than rest (p < 0.0001). The heat test improved ptosis by 1.1 mm less than rest (p = 0.0013). The ice test improved ptosis by 2.3 mm more than the heat test (p < 0.0001). CONCLUSIONS The standardised methodology of ice and heat testing was safe, easily reproducible and effective. We confirm that temperature had a significant effect on ptosis in MG, and therefore refute the notion that measured changes are purely due to the associated rest.
Collapse
Affiliation(s)
- Emmanuel Marinos
- The University of Sydney. Sydney, Australia, Postal address: 6 Byron Street, Coogee, NSW, 2034, Australia.
| | | | | | - Stephen Reddel
- Concord Repatriation General Hospital, Sydney, NSW, Australia
| |
Collapse
|
18
|
Saidi T, Sivarasu S, Douglas TS. Open source modular ptosis crutch for the treatment of myasthenia gravis. Expert Rev Med Devices 2018; 15:137-143. [PMID: 29271663 DOI: 10.1080/17434440.2018.1421455] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
INTRODUCTION Pharmacologic treatment of Myasthenia Gravis presents challenges due to poor tolerability in some patients. Conventional ptosis crutches have limitations such as interference with blinking which causes ocular surface drying, and frequent irritation of the eyes. To address this problem, a modular and adjustable ptosis crutch for elevating the upper eyelid in Myasthenia Gravis patients has been proposed as a non-surgical and low-cost solution. AREAS COVERED This paper reviews the literature on the challenges in the treatment of Myasthenia Gravis globally and focuses on a modular and adjustable ptosis crutch that has been developed by the Medical Device Laboratory at the University of Cape Town. EXPERT COMMENTARY The new medical device has potential as a simple, effective and unobtrusive solution to elevate the drooping upper eyelid(s) above the visual axis without the need for medication and surgery. Access to the technology is provided through an open source platform which makes it available globally. Open access provides opportunities for further open innovation to address the current limitations of the device, ultimately for the benefit not only of people suffering from Myasthenia Gravis but also of those with ptosis from other aetiologies.
Collapse
Affiliation(s)
- Trust Saidi
- a Department of Human Biology , Division of Biomedical Engineering, University of Cape Town , Cape Town , South Africa
| | - Sudesh Sivarasu
- a Department of Human Biology , Division of Biomedical Engineering, University of Cape Town , Cape Town , South Africa
| | - Tania S Douglas
- a Department of Human Biology , Division of Biomedical Engineering, University of Cape Town , Cape Town , South Africa
| |
Collapse
|
19
|
Myasthenia Gravis. Neuromuscul Disord 2018. [DOI: 10.1007/978-981-10-5361-0_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Park JY, Yang HK, Hwang JM. Diagnostic value of repeated ice tests in the evaluation of ptosis in myasthenia gravis. PLoS One 2017; 12:e0177078. [PMID: 28562609 PMCID: PMC5451013 DOI: 10.1371/journal.pone.0177078] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 04/21/2017] [Indexed: 12/04/2022] Open
Abstract
Twenty-six patients with ptosis related to Myasthenia gravis (MG) and 38 controls with ptosis other than MG were included. All patients were tested with the ice test 2 times on separate days in the afternoon. The margin reflex distance (MRD) was measured before and immediately after 2-minute application of ice on the eyelids. The ice test was judged positive if there was an improvement of at least 2.0 mm of MRD after the ice test. Among the patients with negative test results, 'equivocal' was defined by improvement of MRD from at least 1.0 mm to less than 2.0 mm after the ice test. Repeated ice test results showed an agreement of 61.5% in MG, and 97.4% in nonmyasthenic ptosis. Repeated ice tests increased the sensitivity by 34.6% compared to a single test. Among the patients with repeatedly negative test results, 63.6% of those who showed equivocal results at least once turned out to be MG. Of those with repeated non-equivocal negative results, nobody turned out to be MG. There was no significant difference of the ice test results between ocular MG and generalized MG (p = 0.562).
Collapse
Affiliation(s)
- Jun Young Park
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
| | - Hee Kyung Yang
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
| | - Jeong-Min Hwang
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
| |
Collapse
|
21
|
Abstract
Myasthenia gravis is a disorder of neuromuscular transmission that leads to fatigue of skeletal muscles and fluctuating weakness. Myasthenia that affects children can be classified into the following 3 forms: transient neonatal myasthenia, congenital myasthenic syndromes, and juvenile myasthenia gravis (JMG). JMG is an autoimmune disorder that has a tendency to affect the extraocular muscles, but can also affect all skeletal muscles leading to generalized weakness and fatigability. Respiratory muscles may be involved leading to respiratory failure requiring ventilator support. Diagnosis should be suspected clinically, and confirmatory diagnostic testing be performed, including serum acetylcholine receptor antibodies, repetitive nerve stimulation, and electromyography. Treatment for JMG includes acetylcholinesterase inhibitors, immunosuppressive medications, plasma exchange, intravenous immunoglobulins, and thymectomy. Children with myasthenia gravis require monitoring by a pediatric ophthalmologist for the development of amblyopia from ptosis or strabismus.
Collapse
|
22
|
Nair AG, Patil-Chhablani P, Venkatramani DV, Gandhi RA. Ocular myasthenia gravis: a review. Indian J Ophthalmol 2016; 62:985-91. [PMID: 25449931 PMCID: PMC4278125 DOI: 10.4103/0301-4738.145987] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Myasthenia gravis (MG) is a disease that affects the neuro-muscular junction resulting in classical symptoms of variable muscle weakness and fatigability. It is called the great masquerader owing to its varied clinical presentations. Very often, a patient of MG may present to the ophthalmologist given that a large proportion of patients with systemic myasthenia have ocular involvement either at presentation or during the later course of the disease. The treatment of ocular MG involves both the neurologist and ophthalmologist. Thus, the aim of this review was to highlight the current diagnosis, investigations, and treatment of ocular MG.
Collapse
Affiliation(s)
| | - Preeti Patil-Chhablani
- Department of Strabismus and Neuro-Ophthalmology, Jasti V Ramanamma Children's Eye Care Centre, Hyderabad, Telangana, India
| | | | | |
Collapse
|
23
|
Variable ptosis after botulinum toxin type a injection with positive ice test mimicking ocular myasthenia gravis. J Neuroophthalmol 2014; 33:169-71. [PMID: 23681240 DOI: 10.1097/wno.0b013e31828bb19b] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
We describe a patient who received cosmetic botulinum toxin type A injections to the brow and subsequently developed unilateral ptosis that was variable during examination and was transiently improved after the ice pack test. Ptosis gradually resolved spontaneously over approximately 3 months. This is the third patient to have variable ptosis documented after botulinum toxin type A injection to the brow and the second to have a positive ice test. The ice test is not completely specific for myasthenia gravis but may, at times, improve ptosis resulting from other defects at the neuromuscular junction. Wound botulism now is much more common because of illicit drug use, and the ice test also might be positive in this setting.
Collapse
|
24
|
Fakiri MO, Tavy DL, Hama-Amin AD, Wirtz PW. Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis. Muscle Nerve 2013; 48:902-4. [DOI: 10.1002/mus.23857] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/21/2013] [Indexed: 11/09/2022]
Affiliation(s)
- M. Omeed Fakiri
- Department of Neurology; Haga Teaching Hospitals; Leyweg 275, 2545 CH The Hague The Netherlands
| | - Dénes L.J. Tavy
- Department of Neurology; Haga Teaching Hospitals; Leyweg 275, 2545 CH The Hague The Netherlands
| | - Ako Dara Hama-Amin
- Department of Neurology; Haga Teaching Hospitals; Leyweg 275, 2545 CH The Hague The Netherlands
| | - Paul W. Wirtz
- Department of Neurology; Haga Teaching Hospitals; Leyweg 275, 2545 CH The Hague The Netherlands
| |
Collapse
|
25
|
Cosmetic botulinum toxin type A induced ptosis presenting as myasthenia. Ophthalmic Plast Reconstr Surg 2012; 27:470. [PMID: 22072210 DOI: 10.1097/iop.0b013e3182364980] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Pruitt JA, Ilsen PF. On the frontline: what an optometrist needs to know about myasthenia gravis. ACTA ACUST UNITED AC 2010; 81:454-60. [PMID: 20655284 DOI: 10.1016/j.optm.2009.09.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2008] [Revised: 09/11/2009] [Accepted: 09/25/2009] [Indexed: 10/19/2022]
Abstract
BACKGROUND Myasthenia gravis (MG) is an autoimmune disease that affects the voluntary skeletal muscles. It is characterized by transient weakness of the muscles that improves with rest. Muscle weakness involving the eyes can produce signs or symptoms of diplopia, blurred vision, ptosis, and ophthalmoplegia. Ptosis is defined as an abnormal eyelid "drooping" beyond the normal 1 to 2 mm of the upper limbus of the cornea. Hence, most patients with MG have ophthalmic manifestations. Among all patients with MG, up to half will have exclusively ocular symptoms. In these cases, the condition is referred to as ocular myasthenia. CASE REPORT A 60-year-old man was referred from a neurology clinic for management of intermittent diplopia for greater than 1 year and intermittent bilateral ptosis for the prior year. He reported that he first noticed symptoms of MG at the age of 42, but did not receive the diagnosis until 1 year before his aforementioned neurology examination. He was prescribed spectacles with bilateral ptosis crutches. A diagnosis of severe seronegative MG was subsequently confirmed with neurologic examination and antibody testing. CONCLUSIONS Because patients with undiagnosed myasthenia gravis may present initially with ocular signs or symptoms, it is important for the optometrist to be familiar with the condition and the simple "in-office" tests that can be performed to establish a tentative diagnosis and management plan. The optometrist can also participate in the management of ocular manifestations of myasthenia and should be familiar with the use of a ptosis crutch (in addition to prism spectacles or occlusion therapies if indicated) as a nonsurgical intervention for ptosis.
Collapse
Affiliation(s)
- Joseph A Pruitt
- Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA.
| | | |
Collapse
|
27
|
|
28
|
Liu GT, Volpe NJ, Galetta SL. Eyelid and facial nerve disorders. Neuroophthalmology 2010. [DOI: 10.1016/b978-1-4160-2311-1.00014-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
29
|
Bodack MI. Ptosis and cranial nerve IV palsy reveal juvenile myasthenia gravis. OPTOMETRY (ST. LOUIS, MO.) 2009; 80:342-349. [PMID: 19545846 DOI: 10.1016/j.optm.2008.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2007] [Revised: 02/19/2008] [Accepted: 03/04/2008] [Indexed: 05/28/2023]
Abstract
BACKGROUND Ptosis and strabismus are 2 common presenting complaints of preschool-age patients. In both cases, these conditions can be benign and require no further workup. However, sudden onset of these findings can indicate a more serious neurologic problem. If a patient presents with multiple neurologic signs, a sudden onset eye turn, or ptosis, the patient must undergo a workup to rule out a pathologic etiology, specifically a brain tumor. The workup should include neuroimaging. If the results of the neuroimaging are normal, and the findings are variable, myasthenia gravis should be considered, and additional testing should be ordered to assist in the diagnosis. CASE REPORT This case report presents a 3-year-old boy who presented with a sudden onset of ptosis and hypertropia. Diagnosis of myasthenia gravis was made based on clinical presentation and response to ice pack testing. The patient was treated with pyridostigmine (Mestinon; Valent Pharmaceuticals, Costa Mesa, California) and has shown improvement in his clinical signs. CONCLUSIONS Although rare, myasthenia should be considered a diagnosis in children who present with variable ptosis or strabismus. Patients can be successfully treated with medication.
Collapse
Affiliation(s)
- Marie I Bodack
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA.
| |
Collapse
|
30
|
Farrugia ME, Weir AI, Cleary M, Cooper S, Metcalfe R, Mallik A. Concentric and single fiber needle electrodes yield comparable jitter results in myasthenia gravis. Muscle Nerve 2009; 39:579-85. [DOI: 10.1002/mus.21151] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
31
|
Friedman DI. Disorders of the Neuromuscular Junction. Ophthalmology 2009. [DOI: 10.1016/b978-0-323-04332-8.00171-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
32
|
Abstract
PURPOSE OF REVIEW Increasing rigor is being applied to medical decision making, but myasthenia gravis, commonly considered the best understood autoimmune disorder from a pathophysiological basis, lags other disciplines in the evidence base used to make clinical decisions. The review attempts to provide a focused, practical guideline for the diagnosis and treatment of ocular myasthenia within the limits of largely retrospective case series and expert opinion. RECENT FINDINGS Confirmation of clinical diagnosis continues to be challenging for ocular myasthenia. Despite the recognition of a new autoantigen, the muscle-specific kinase protein in generalized myasthenia gravis, it has been found to be only rarely identified in ocular myasthenia patients and therefore the majority of patients lack detectable autoantibodies and confirmation of a neuromuscular transmission disorder relies on specialized testing of single-fiber electromyography. The visual compromise of ocular myasthenia responds poorly to nonpharmacological and cholinesterase inhibitor therapy, and although corticosteroids are thought to be extremely effective, their toxicity is poorly defined in ocular myasthenia patients and whether they reduce the risk of development of generalized disease is not known. SUMMARY Rigorous clinical trials or large databases with outcome assessments are necessary in order to allow development of rational treatment strategies.
Collapse
|
33
|
Almeida DFD, Radaeli RDF, Melo Jr ACMNC. Ice pack test in the diagnosis of myasthenia gravis. ARQUIVOS DE NEURO-PSIQUIATRIA 2008; 66:96-8. [DOI: 10.1590/s0004-282x2008000100025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
34
|
Abstract
BACKGROUND Although myasthenia gravis (MG) is often considered the best-understood autoimmune disorder and effective treatments have controlled life-threatening complications, the pathogenesis of ocular myasthenia (OM) remains enigmatic, and its clinical consequences offer therapeutic challenges. REVIEW SUMMARY About half of patients with MG present with visual complaints of droopy eyelids or double vision, and many will remain with purely ocular muscle weakness without generalized weakness, defined as OM. OM may be confused with disorders of the brainstem, ocular motor nerves, and eye muscles. Frustrating for the clinician, confirmatory tests such as the edrophonium test, serum acetylcholine receptor antibodies, and standard electrodiagnostic evaluations may fail to positively identify the clinical suspicion of OM. Patients may derive relief from nonpharmacologic interventions and cholinesterase inhibitors, but most will desire better symptom control with corticosteroids or need other immunosuppression. Early corticosteroid therapy may reduce the probability of generalization of the disease. The reasons for ocular muscle involvement by OM include physiologic and cellular properties of the ocular motor system and the unique immunology of OM, which, when better understood, will lead to novel treatments. CONCLUSIONS OM is a challenging disorder for the clinician and scientist, with both learning from the other for the betterment of the patient. The future requires answers to why the ocular muscles are so frequently involved by MG, whether the generalization of the disease may be limited by early corticosteroid treatment, and what treatment options may be developed which will improve symptoms without long-term complications.
Collapse
Affiliation(s)
- Linda L Kusner
- Department of Neurology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA
| | | | | |
Collapse
|
35
|
Affiliation(s)
- Molly E Gilbert
- Wills Eye Institute, 840 Walnut Street Suite 930, Philadelphia, PA 19107, USA
| | | |
Collapse
|
36
|
Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006; 16:459-67. [PMID: 16793269 DOI: 10.1016/j.nmd.2006.05.006] [Citation(s) in RCA: 169] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2006] [Revised: 05/05/2006] [Accepted: 05/09/2006] [Indexed: 10/24/2022]
Abstract
We performed a systematic review to identify studies that reported the accuracy of tests for the diagnosis of myasthenia gravis. We identified 20 studies of reasonable, although variable, methodological quality upon which to base estimates of the accuracy of the ice test, rest test, Tensilon test, acetylcholine receptor antibodies, repetitive nerve stimulation and single fiber electromyography for the diagnosis of myasthenia gravis. After examining inter-study heterogeneity for each diagnostic modality, we calculated pooled estimates of sensitivity and specificity as well as positive and negative likelihood ratios. Results are reported separately for ocular and generalized myasthenia. Studies that have examined the performance of anti-acetylcholine receptor antibody testing and single fiber electromyography were generally of better quality than those that examined other diagnostic modalities. We suggest that caution should be exercised in the interpretation of the diagnostic performance of these tests given the methodological limitations of the studies upon which test performance is based.
Collapse
Affiliation(s)
- Michael Benatar
- Department of Neurology, Emory University, 1365A Clifton Road NE, Atlanta, GA 30322, USA.
| |
Collapse
|
37
|
Colavito J, Cooper J, Ciuffreda KJ. Non-ptotic ocular myasthenia gravis: a common presentation of an uncommon disease. ACTA ACUST UNITED AC 2005; 76:363-75. [PMID: 16038863 DOI: 10.1016/j.optm.2005.05.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/26/2005] [Indexed: 11/21/2022]
Abstract
BACKGROUND Myasthenia gravis (MG) is an acquired autoimmune disease of the neuromuscular junction which causes rapid muscle fatigue and weakness. Two thirds of all cases of myasthenia gravis (MG) initially manifest ptosis. In the absence of the characteristic variable ptosis, MG can present a challenge to the clinician. This article will review the current diagnostic and management strategies for MG. CASE REPORTS Five cases will be presented that did not initially present with ptosis. Each of these cases was previously misdiagnosed as a result of presentation of atypical myasthenia gravis signs and symptoms. The first two cases had signs and symptoms of a typical accommodative/vergence anomaly. The others manifested diplopia not normally associated with MG: one had a noncomitant vertical deviation; another had a stable 6(th) nerve palsy; and the third had a basic esotropia. CONCLUSION Although the hallmark findings of MG are ptosis and eye muscle palsy with variability, MG may present without ptosis, affect nonstriated muscles, and/or manifest either as a nonstrabismic vergence anomaly or as comitant nonvariable strabismic deviation.
Collapse
|
38
|
Abstract
A variety of acute neurologic disorders present with visual signs and symptoms. In this review the authors focus on those disorders in which the clinical outcome is dependent on timely and accurate diagnosis. The first section deals with acute visual loss, specifically optic neuritis, ischemic optic neuropathy (ION), retinal artery occlusion, and homonymous hemianopia. The authors include a discussion of those clinical features that are helpful in distinguishing between inflammatory and ischemic optic nerve disease and between arteritic and nonarteritic ION. The second section concerns disc edema with an emphasis on the prevention of visual loss in patients with increased intracranial pressure. The third section deals with abnormal ocular motility, and includes orbital inflammatory disease, carotid-cavernous fistulas, painful ophthalmoplegia, conjugate gaze palsies, and neuromuscular junction disorders. The final section concerns pupillary abnormalities, with a particular emphasis on the dilated pupil and on carotid artery dissection. Throughout there are specific guidelines for the management of these disorders, and areas are highlighted in which there is ongoing controversy.
Collapse
Affiliation(s)
- Valerie Purvin
- Indiana University Medical Center, Department of Ophthalmology, Indianapolis, IN 46280, USA.
| | | |
Collapse
|
39
|
Abstract
BACKGROUND Diplopia is a common complaint in both inpatient and outpatient neurologic practice. Its causes are many, and special historical and examination features are important to localization and accurate diagnosis. REVIEW SUMMARY This review is divided into 2 sections: the first related to diagnosis and the second to treatment of binocular diplopia. In the diagnostic section, emphasis is placed on identification of historical and examination features that can help to differentiate diplopia caused by dysfunction of cranial nerves versus neuromuscular junction, or orbital extraocular muscle. Techniques available to the neurologist for examining ocular motility and ocular misalignment and focused laboratory testing to evaluate diplopia are discussed in detail. The final section covers the various treatments for binocular diplopia, with recommendations regarding the utility of each treatment for different types of diplopia. CONCLUSIONS A logical step-by-step approach applied to each patient with diplopia will help prevent misdiagnosis and improve patient care.
Collapse
Affiliation(s)
- Janet C Rucker
- Department of Neurology and Ophthalmology, Case Western Reserve School of Medicine, Cleveland, Ohio 44106, USA.
| | | |
Collapse
|
40
|
Ahmed S, Kirmani JF, Janjua N, Alkawi A, Khatri I, Yahia AM, Souyah N, Qureshi AI. An Update on Myasthenic Crisis. Curr Treat Options Neurol 2005; 7:129-141. [PMID: 15676116 DOI: 10.1007/s11940-005-0022-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Myasthenia gravis (MG) is the most common disorder of the neuromuscular junction. Myasthenia crisis, defined as respiratory failure requiring mechanical ventilation in MG, is a common life-threatening complication that occurs in approximately 15% to 20% of patients with MG during their life time. The advent of effective mechanical ventilation, specialized neurointensive care units and the widespread use of immunotherapies have substantially altered the prognosis of myasthenic crisis. Early intubation and mechanical ventilation is perhaps the most important step in the management of myasthenic crisis. The authors favor an orotracheal approach for intubation, and placement of small bore duodenal tubes that may help decrease the risk of aspiration and may be more comfortable than regular nasogastric tubes for the patient. Plasma exchange may be more effective than the intravenous immunoglobulin in the treatment of myasthenic crisis involving respiratory failure. A randomized trial is required to confirm the superior efficacy of plasma exchange compared with intravenous immunoglobulin. In the acute setting, the role of immunosuppression and intravenous/intramuscular pyridostigmine and the newer agents such as tacrolimus remains limited and at times controversial. The therapy should be tailored at an individual basis using best clinical judgment.
Collapse
Affiliation(s)
- Shafiuddin Ahmed
- Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, Newark, NJ 07101, USA.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Myasthenia gravis is an autoimmune disorder caused by autoantibodies against the nicotinic acetylcholine receptor on the postsynaptic membrane at the neuromuscular junction and characterised by weakness and fatigability of the voluntary muscles. It has a bimodal peak of incidence with first peak in the third decade and the second peak in the sixth decade. It is probably underdiagnosed in the very old population. Our understanding of the pathogenesis, immunology, and molecular biology of myasthenia gravis has greatly improved in last three decades. It is almost always possible to establish the diagnosis of myasthenia gravis with the current tests. The modern treatment is highly successful and the mortality of treated myasthenia gravis is practically zero. However, there are still important gaps in our knowledge of the origin of myasthenia gravis, the factors that contribute to chronic disease, and the way to cure the disease. In this article the current knowledge of the various aspects of myasthenia gravis are outlined.
Collapse
Affiliation(s)
- B R Thanvi
- Department of Integrated Medicine, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK.
| | | |
Collapse
|
42
|
Abstract
In the evaluation of ptosis, the ice pack test is a simple, quick, bedside method to ascertain whether it is of myasthenic origin, which requires no specialised medication or equipment and is free of reported adverse effects. Pooling of published studies suggests very high sensitivity, specificity and likelihood ratios, but standardisation and operationalisation of the test are important. False-negative tests may occasionally occur.
Collapse
Affiliation(s)
- A J Larner
- Walton Centre for Neurology and Neurosurgery, Fazakerly, Liverpool, UK.
| |
Collapse
|
43
|
|
44
|
Affiliation(s)
- Jay M Stewart
- Department of Ophthalmology, University of California, San Francisco 94143, USA
| | | |
Collapse
|
45
|
Affiliation(s)
- Roger E Bassin
- Ophthalmic Plastic and Reconstructive Surgery, University of Illinois, Chicago, Michael Reese Hospital, 60602, USA
| | | |
Collapse
|
46
|
Abstract
This review focuses on the diagnostic tests that may help to confirm myasthenia in patients without acetylcholine receptor antibodies, including the newly discovered anti-muscle-specific receptor tyrosine kinase antibody and other investigations. We discuss management dilemmas, particularly those that revolve around treatments whose efficacy is questionable or unproved, such as thymectomy. We review the important issue of how treatments are assessed, and examine future treatment trial designs.
Collapse
Affiliation(s)
- J Palace
- University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK
| | | | | |
Collapse
|
47
|
de Faber JT, van Everdingen JA, Kingma-Wilschut C. Neuro-ophthalmologic manifestations of systemic disease and neurologic disease. Curr Opin Ophthalmol 2001; 12:373-7. [PMID: 11588501 DOI: 10.1097/00055735-200110000-00009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- J T de Faber
- The Rotterdam Eye Hospital, Rotterdam, The Netherlands.
| | | | | |
Collapse
|
48
|
Author reply. Ophthalmology 2001. [DOI: 10.1016/s0161-6420(01)00613-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|